Skip to main content
NAMS
NASDAQ Life Sciences

Frazier Life Sciences Funds Buy $2.3M of NewAmsterdam Pharma Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$23.32
Mkt Cap
$2.788B
52W Low
$21.02
52W High
$42.205
52W Position info
11% above low
Off High info
45% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

NAMS is trading near its 52-week low of $21.02 (11% above the low) on elevated volume (2.2× avg).

Summary

Frazier Life Sciences funds bought $2.3M of NewAmsterdam Pharma stock in September 2026, increasing their stake to 6.1%.


Key Events · Ownership and Investor Activity · NAMS

  • Frazier Funds Buy $2.3M in Shares

    Frazier Life Sciences Public Fund, XI, and XII purchased approximately $2.3 million of NewAmsterdam Pharma shares across 12 trading days in September 2026, at prices ranging from $21.08 to $25.50.

  • Stake Increases to 6.1%

    The purchases increase Frazier Life Sciences X, L.P.'s beneficial ownership to 7,329,857 shares (6.1% of outstanding), with the broader Frazier group holding approximately 18.2% collectively.

  • Purchases Follow EU Approval

    The buying occurred after the European Commission granted marketing authorization for obicetrapib monotherapy and its fixed-dose combination on September 21, 2026.

  • Institutional Conviction

    Frazier Life Sciences is a dedicated life sciences venture capital firm, and these open-market purchases represent a meaningful capital commitment to NewAmsterdam Pharma's commercial launch.


Analysis · NAMS · Life Sciences

Frazier Life Sciences funds purchased approximately $2.3 million of NewAmsterdam Pharma shares across multiple transactions in September 2026, at prices ranging from $21.08 to $25.50. This is a significant accumulation by a major life sciences investor, adding to their existing 6.1% stake in the company. The purchases come just days after the European Commission granted marketing authorization for obicetrapib, suggesting institutional confidence in the company's commercial prospects.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAMS was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $21.02 to $42.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.32 info
Change: -$2.37 (-11%) info
Market Cap: $2.208B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info
NAMS
Aug 05, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.32 info
Change: -$9.20 (-33%) info
Market Cap: $2.208B info